Randomized trial reveals beneficial effects of ipragliflozin matching pioglitazone on steatotic liver disease in type 2 diabetes, suggesting durable long-term therapeutic equivalence.
We conducted a 5 year post-trial monitoring study of our previous randomized 24 week, open-label, active-controlled trial that showed beneficial effects of ipragliflozin on metabolic dysfunction-associated steatotic liver disease (MASLD), identical to those of pioglitazone.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: